Bioxytran Secures Free Sale Certification for A-SUQAR®
The certification opens a path to the UAE and Gulf markets for the chewable nutraceutical.
Related stories
Glenmark Q2 Profit Falls 56.8% on Lower North America Sales
Glenmark Pharmaceuticals reported consolidated net profit of 2.64 billion rupees for the quarter ended September 30, down 56.8% as North America revenue fell.
M impact | EQUITY | Nov 05, 2026, 02:14 PM UTC
HCW Biologics Secures $10.2 Million in Notes Financing
HCW Biologics entered into a purchase agreement for $10.2 million in secured notes, closing November 4, 2026. The financing comprises a $3.2 million A-1 Note and a $7.0 million B N
M impact | EQUITY | Nov 05, 2026, 02:13 PM UTC
Myriad Genetics Reports Unauthorized Network Access, Most Systems Restored
Myriad Genetics detected unauthorized access to its IT network and says most systems have returned to normal operations.
M impact | EQUITY | Nov 05, 2026, 02:13 PM UTC
BP Sells 5% Stake in Aker BP at 12% Discount
BP sold a 5% stake in Aker BP at 311 Norwegian kroner per share, a 12% discount to Aker BP’s Wednesday closing price of 354 kroner. Citi analysts called the sale sensible and said
M impact | EQUITY | Nov 05, 2026, 02:12 PM UTC
Victory Capital Reports Third-Quarter Revenue of $396.57 Million, EPS of $1.11
Revenue rose 10% year over year as higher average AUM lifted investment management fees. Net income attributable to common stockholders declined; earnings reflected increased perso
M impact | EQUITY | Nov 05, 2026, 02:11 PM UTC
Wheels Up Reports Third-Quarter 2026 Revenue of $164.79 Million, EPS Loss of $2.48
Revenue fell 11% year over year and net loss widened 7%. Lower flight volume and membership revenue weighed on results, partly offset by higher revenue per flight leg and lower ope
M impact | EQUITY | Nov 05, 2026, 02:11 PM UTC